Compare Cytokinetics Inc (CYTK) vs Mondaycom Ltd (MNDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Mondaycom Ltd — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Mondaycom Ltd trades at $88.96 (market cap $3.76B). The key difference: Cytokinetics Inc is far larger — about 2.3× Mondaycom Ltd's market cap, and Mondaycom Ltd is more actively traded (836,200 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Mondaycom Ltd for 16 Days on average.
| CYTK | MNDY | |
|---|---|---|
Market Cap | $8.62B | $3.76B |
Volume | 2,594,626 | 836,200 |
Sector | Health | Technology |
52-Week High | $87.26 | $205.24 |
52-Week Low | $54.76 | $58.81 |
Typical Hold Time | 19 Days | 16 Days |
Enterprise Value | $8.72B | $2.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% today, amid bearish technical signals but strong analyst optimism. The stock shows negative profitability with a -1,321.12% net income margin and P/S ratio of 114, reflecting high growth expectations. Recent Phase 3 trial successes for aficamten in hypertrophic cardiomyopathy position the company for potential FDA approval and commercial expansion, driving the 97% buy rating consensus with a $112.60 price target.
The outlook balances clinical progress against financial strain. While aficamten's recent data and commercial launch of MYQORZO offer significant upside, persistent cash burn and high valuation multiples present substantial risk. Investors face binary outcomes dependent on regulatory success and market penetration versus ongoing operational losses.
Monday.com (MNDY) trades at $88.91, up 6.47% over the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical stance with moving averages supporting the uptrend, while fundamentals show robust revenue growth to $1.23 billion in 2025 and consistent earnings beats. Recent news highlights inclusion in growth stock lists and positive coverage around its AI-focused Elevate '26 conference, signaling investor optimism and product innovation.
The outlook for MNDY remains positive given analyst consensus favoring buys and a price target of $108.64, though elevated valuation ratios like a P/E of 37.69 pose risks if growth slows. Key opportunities include enterprise client expansion and AI integration, while risks involve competitive pressures and market volatility. Investors should weigh strong execution against premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →
